Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, presents expanded data from the microsatellite stable colorectal (MSS-CRC) expansion cohort of the Phase I study of botensilimab (NCT03860272), a multifunctional Fc-enhanced anti-CTLA-4, in combination with balstilimab, an anti-PD1 antibody, in metastatic heavily pre-treated MSS CRC. Efficacy was especially higher in patients without liver metastases, which form a significant minority of patients with MSS-CRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

A combination of the next-generation immunotherapies botensilimab and balstilimab showed clinical activity in treating patients with refractory metastatic microsatellite-stable (MSS) colorectal cancer, according to new findings presented by El-Khoueiry et al at the 2023 ASCO Gastrointestinal Cancers Symposium (Abstract LBA8).

Fifteen months after the FDA blindsided Agenus with a decision not to offer accelerated approval for the cervical cancer drug balstilimab, the biotech is back with fresh data for a combo featuring the therapy it claims could finally make headway.

A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.